This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignees: Astrazeneca Ab, Ionis Pharmaceuticals, Inc.. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 1,534 
1 out of 288 
Years Active: 2024
Title: Eric Valeur: Innovator in GLP-1 Receptor Targeting
Introduction
Eric Valeur is a notable inventor based in Mölndal, Sweden. He has made significant contributions to the field of biotechnology, particularly in the development of compounds that target specific cellular receptors. His work has implications for various therapeutic applications.
Latest Patents
Eric Valeur holds a patent for "GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof." This patent describes compounds and methods for targeting cells that express the GLP-1 receptor. The innovation aims to enhance the efficacy of treatments related to metabolic disorders.
Career Highlights
Throughout his career, Eric has worked with prominent companies in the pharmaceutical industry. He has been associated with AstraZeneca AB and Ionis Pharmaceuticals, Inc. His experience in these organizations has allowed him to contribute to cutting-edge research and development in drug discovery.
Collaborations
Eric Valeur has collaborated with notable professionals in his field, including Brett P. Monia and Thazha P. Prakash. These collaborations have further enriched his research and innovation efforts.
Conclusion
Eric Valeur's work exemplifies the intersection of innovation and biotechnology. His contributions to GLP-1 receptor targeting represent a significant advancement in therapeutic strategies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile